Table 1 Hepatotoxicity related to erlotinib administration
From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
Characteristics | All patients | Lung cancer | Pancreatic cancer | |||
|---|---|---|---|---|---|---|
Hepatotoxicity No (%) | Hepatotoxicity No (%) | Hepatotoxicity No (%) | ||||
Presence (n = 62) | Absence (n = 298) | Presence (n = 16) | Absence (n = 139) | Presence (n = 46) | Absence (n = 159) | |
Age (years) | ||||||
< 65 | 28 (45.2) | 155 (52.0) | 6 (37.5) | 85 (61.2) | 22 (47.8) | 70 (44.0) |
≥ 65 | 34 (54.8) | 143 (48.0) | 10 (62.5) | 54 (38.8) | 24 (52.2) | 89 (56.0) |
Sex | ||||||
Male | 35 (56.5) | 182 (61.1) | 8 (50.0) | 87 (62.6) | 27 (58.7) | 95 (59.7) |
Female | 27 (43.5) | 116 (38.9) | 8 (50.0) | 52 (37.4) | 19 (41.3) | 64 (40.3) |
BW (kg) | ||||||
< 60 | 38 (61.3) | 162 (54.4) | 6 (37.5) | 70 (50.4) | 32 (69.6) | 92 (57.9) |
≥ 60 | 24 (38.7) | 136 (45.6) | 10 (62.5) | 69 (49.6) | 14 (30.4) | 67 (42.1) |
Height (cm)a | ||||||
< 160 | 27 (43.5) | 115 (38.7) | 8 (50.0) | 45 (32.4) | 19 (41.3) | 70 (44.3) |
≥ 160 | 35 (56.5) | 182 (61.3) | 8 (50.0) | 94 (67.6) | 27 (58.7) | 88 (55.7) |
BSAb | ||||||
< 1.6 | 32 (51.6) | 130 (43.8) | 5 (31.3) | 54 (38.8) | 27 (58.7) | 76 (48.1) |
≥ 1.6 | 30 (48.4) | 167 (56.2) | 11 (68.6) | 85 (61.2) | 19 (41.3) | 82 (51.9) |
Stagec | ||||||
1–3 | 6 (14.3) | 27 (14.4) | 0 (0.0) | 5 (5.0) | 6 (20.7) | 22 (25.0) |
4 | 36 (85.7) | 161 (85.6) | 13 (100.0) | 95 (95.0) | 23 (79.3) | 66 (75.0) |
CV | ||||||
Yes | 15 (24.2) | 83 (27.9) | 1 (6.3) | 25 (18.0) | 14 (30.4) | 58 (36.5) |
No | 47 (75.8) | 215 (72.1) | 15 (93.8) | 114 (82.0) | 32 (69.6) | 101 (63.5) |
DM | ||||||
Yes | 18 (29.0) | 66 (22.1) | 1 (6.3) | 17 (12.2) | 17 (37.0) | 49 (30.8) |
No | 44 (71.0) | 232 (77.9) | 15 (93.8) | 122 (87.8) | 29 (63.0) | 110 (69.2) |
EGFR mutationsd | ||||||
Yes | 9 (81.8) | 76 (69.1) | 9 (81.8) | 76 (69.1) | NA | NA |
No | 2 (18.2) | 34 (30.9) | 2 (18.2) | 34 (30.9) | NA | NA |
Liver metastasis | ||||||
Yes | 19 (30.6) | 61 (20.5) | 2 (12.5) | 11 (7.9) | 17 (37.0) | 50 (31.4) |
No | 43 (69.4) | 237 (79.5) | 14 (87.5) | 128 (92.1) | 29 (63.0) | 109 (68.6) |
CYP3A4 Inhibitor | ||||||
Yes | 3 (4.8) | 15 (5.0) | 2 (12.5) | 10 (7.2) | 1 (2.2) | 5 (3.1) |
No | 59 (95.2) | 283 (95.0) | 14 (87.5) | 129 (92.8) | 45 (97.8) | 154 (96.9) |
CYP3A4 Inducer | ||||||
Yes | 7 (11.3) | 15 (5.0) | 3 (18.8) | 11 (7.9) | 4 (8.7) | 4 (2.5) |
No | 55 (88.7) | 283 (95.0) | 13 (81.3) | 128 (92.1) | 42 (91.3) | 155 (97.5) |
H2 blocker or PPI | ||||||
Yes | 16 (25.8) | 56 (18.8) | 7 (43.8) | 28 (20.1) | 9 (19.6) | 28 (17.6) |
No | 46 (74.2) | 242 (81.2) | 9 (56.3) | 111 (79.9) | 37 (80.4) | 131 (82.4) |
PPI | ||||||
Yes | 7 (11.3) | 23 (7.7) | 4 (25.0) | 12 (8.6) | 3 (6.5) | 11 (6.9) |
No | 55 (88.7) | 275 (92.3) | 12 (75.0) | 127 (91.4) | 43 (93.5) | 148 (93.1) |
H2 blocker | ||||||
Yes | 9 (14.5) | 41 (13.8) | 3 (18.8) | 22 (15.8) | 6 (13.0) | 19 (11.9) |
No | 53 (85.5) | 257 (86.2) | 13 (81.3) | 117 (84.2) | 40 (87.0) | 140 (88.1) |